INZY

Inozyme Pharma, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website inozyme.com
Employees(FY) 56
ISIN US45790W1080

Performance

-25.8%

-49.64%

-42.59%

-39.35%

-34.51%

YTD

-28.46%

Profile

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Advanced Technical Analysis

Technical Analysis of INZY 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of INZY

Stock Rank

Recent News & Updates

2024-11-12 20:35
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks(Yahoo Finance)
2024-11-10 19:30
Inozyme Pharma to Present at Upcoming Investor Conferences(Globenewswire)
2024-11-04 19:30
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights(Globenewswire)
2024-10-24 01:15
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701(Globenewswire)
2024-10-16 20:30
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024(Globenewswire)
2024-10-06 20:30
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors(Globenewswire)
2024-09-25 20:00
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting(Globenewswire)
2024-08-28 20:30
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference(Globenewswire)
2024-08-17 21:03
Jefferies Predicts up to 270% Rally for These 2 Strong Buy Stocks(Yahoo Finance)
2024-08-06 01:52
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024(Investorplace)
2024-08-05 20:30
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights(Globenewswire)
2024-07-24 20:30
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function(Globenewswire)
2024-07-01 20:30
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency(Globenewswire)
2024-06-29 08:37
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?(Insidermonkey)
2024-06-29 06:30
10 Best Biotech Penny Stocks to Buy Now(Insidermonkey)
2024-06-21 01:00
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)(Globenewswire)
2024-05-29 20:30
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-22 20:30
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences(Globenewswire)
2024-05-07 20:30
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference(Globenewswire)
2024-05-07 01:52
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024(Investorplace)
2024-05-06 20:30
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights(Globenewswire)
2024-05-02 20:30
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-04-07 18:30
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency(Globenewswire)
2024-04-05 06:00
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-04-01 20:30
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference(Globenewswire)
2024-03-26 08:30
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024(GlobeNewswire)
2024-03-25 20:30
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024(Globenewswire)
2024-03-12 08:30
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights(GlobeNewswire)
2024-03-11 20:30
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights(Globenewswire)
2024-02-26 08:30
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference(GlobeNewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.